SCF ENCYCLOPEDIA ENTRY

SCF-RDOS INDICATION REGISTRY

PERIPARTUM CARDIOMYOPATHY

SCF-RDOS Registry Code: SCF-RDOS-PPD-CV-001

ICD Alignment: Peripartum Cardiomyopathy (PPCM)

SCF Classification: Postpartum Cardiovascular Disease

SCF Disease Domain: Cardio-Immunometabolic Failure Syndrome

SCF Pathogenesis Tier: Tier IV–VI Systemic Failure Disorder

Clinical Category: Pregnancy-Associated Dilated Cardiomyopathy

SCF Clinical Priority Level: Critical / Life-Threatening

FDA Therapeutic Area: Cardiovascular Disease / Heart Failure

1. DEFINITION

Peripartum Cardiomyopathy (PPCM) is a pregnancy-associated cardiomyopathy characterized by the development of left ventricular systolic dysfunction occurring during the final month of pregnancy or within the first five months postpartum, without another identifiable cause of heart failure.

Clinically, PPCM manifests as:

• Reduced left ventricular ejection fraction (LVEF)
• Ventricular dilation (variable)
• Pulmonary congestion
• Cardiac output failure
• Multisystem hypoperfusion

Within the SCF framework, PPCM is classified as a:

Maternal Bioenergetic–Cardiovascular Collapse Syndrome involving convergence of immune dysregulation, endothelial dysfunction, mitochondrial failure, hormonal maladaptation, and myocardial remodeling.

2. SCF ETIOPATHOGENIC CORE

Primary Disease Drivers

Cardiovascular

• Ventricular remodeling
• Myocardial inflammation
• Microvascular dysfunction
• Reduced cardiac contractility

Endocrine

• Prolactin cleavage dysregulation
• Oxidative stress-mediated hormonal toxicity
• Pregnancy-associated angiogenic imbalance

Immunological

• Cytokine activation
• Autoimmune reactivation
• Postpartum inflammatory rebound

Metabolic

• Mitochondrial dysfunction
• ATP depletion
• Oxidative stress overload

Genetic

Associated susceptibility genes include:

• TTN
• FLNC
• DSP
• BAG3
• LMNA
• MYH7

3. SCF FAULT ARCHITECTURE

4. MOLECULAR MULTI-OMICS PATHOGENESIS MAP

Genomics

Susceptibility mutations:

• TTN truncating variants
• FLNC variants
• DSP mutations
• BAG3 dysfunction

Result:

• Reduced sarcomere stability
• Contractile dysfunction

Transcriptomics

Upregulated:

• TNF-α
• IL-6
• IL-1β
• NF-κB pathways

Downregulated:

• Mitochondrial biogenesis genes
• Angiogenic signaling pathways

Proteomics

Abnormal expression of:

• Matrix metalloproteinases (MMPs)
• Collagen remodeling proteins
• Sarcomeric proteins

Result:

• Ventricular remodeling
• Reduced contractility

Metabolomics

Observed abnormalities:

• ATP depletion
• Reduced fatty acid oxidation
• Mitochondrial inefficiency
• Elevated oxidative metabolites

Epigenomics

Potential contributors:

• Oxidative stress-mediated DNA methylation
• Pregnancy-related transcriptional reprogramming

Interactomics

Major disrupted pathways:

• VEGF signaling
• STAT3 signaling
• PI3K/AKT
• AMPK
• Mitochondrial stress pathways

Connectomics

Consequences:

• Autonomic imbalance
• Sympathetic overactivation
• Vagal withdrawal

Biomechanicalomics

Mechanical alterations:

• Ventricular wall stress
• Chamber dilation
• ECM tension disruption

5. SCF PATHOGENESIS FLOW

Stage 1 — Pregnancy Stress Load

Pregnancy-induced:

• Hemodynamic expansion
• Hormonal fluctuations
• Increased cardiac workload

↓

Stage 2 — Oxidative Stress Escalation

Excess ROS generation

↓

STAT3 suppression

↓

Mitochondrial dysfunction

↓

Stage 3 — Pathologic Prolactin Cleavage

Cathepsin D activation

↓

16-kDa prolactin fragment formation

↓

Antiangiogenic injury

↓

Stage 4 — Endothelial Dysfunction

Reduced VEGF signaling

↓

Microvascular injury

↓

Myocardial ischemic stress

↓

Stage 5 — Myocardial Remodeling

Fibrosis

↓

Ventricular dilation

↓

Reduced ejection fraction

↓

Stage 6 — Clinical Heart Failure

Pulmonary edema

↓

Cardiogenic shock

↓

Arrhythmias

↓

Death (severe cases)

6. CLINICAL PRESENTATION

Early Symptoms

• Fatigue
• Exercise intolerance
• Dyspnea
• Orthopnea
• Palpitations

Progressive Symptoms

• Pulmonary edema
• Persistent cough
• Peripheral edema
• Ascites
• Syncope

Advanced Disease

• Cardiogenic shock
• Ventricular arrhythmias
• Sudden cardiac death
• Thromboembolism

7. DIAGNOSTIC BIOMARKERS

Cardiac Biomarkers

Elevated:

• BNP
• NT-proBNP
• Troponin I
• Troponin T

Imaging

Echocardiography

Diagnostic findings:

• LVEF <45%
• Global hypokinesis
• Ventricular dilation

Cardiac MRI

Assessment of:

• Fibrosis
• Inflammation
• Myocardial remodeling

8. SCF THERAPEUTIC MECHANISMS

A. SCF-PCR PREVENTATIVE MODULE

Objectives

Prevent myocardial injury before overt heart failure develops.

Targets:

• Oxidative stress
• Endothelial dysfunction
• Mitochondrial preservation

Potential intervention classes:

• Antioxidant therapies
• Mitochondrial stabilizers
• Endothelial support agents

B. SCF-PCR CURATIVE MODULE

Objectives

Restore myocardial function.

Targets:

• Neurohormonal activation
• Ventricular remodeling
• Inflammatory signaling

Therapeutic classes:

• Guideline-directed heart failure therapies
• Bromocriptine-based prolactin suppression (selected cases)
• Anti-remodeling interventions

C. SCF-PCR RESTORATIVE MODULE

Objectives

Promote myocardial regeneration and long-term recovery.

Targets:

• Mitochondrial recovery
• ECM remodeling normalization
• Neurohormonal rebalancing

Potential strategies:

• Regenerative biologics
• Mitochondrial restoration platforms
• Precision cardiac rehabilitation

9. RESISTANCE & OFF-TARGET MODELING

Potential Failure Nodes

10. PROGNOSIS STRATIFICATION

Favorable Prognosis

• LVEF >35%
• Early diagnosis
• Minimal ventricular dilation
• Rapid treatment initiation

Intermediate Prognosis

• Persistent LV dysfunction
• Delayed diagnosis
• Moderate remodeling

High-Risk Prognosis

• LVEF <25%
• Cardiogenic shock
• Severe ventricular dilation
• Ventricular arrhythmias

11. SCF THERAPEUTIC TARGET MAP

12. PROJECT RHENOVA INTEGRATION PATHWAYS

RHENOVA-CARDIO-PPCM

Research Modules

Module A

Maternal cardiac bioenergetic failure mapping

Module B

Prolactin-fragment toxicodynamics

Module C

Endothelial–mitochondrial interaction modeling

Module D

Fibrosis reversal and ECM reconstruction

Module E

Precision postpartum cardiomyopathy therapeutic engineering

13. NEXT STRATEGIC RESEARCH PATHWAYS

Priority 1

Multi-omic PPCM patient atlas development.

Priority 2

Prolactin-fragment biomarker stratification platform.

Priority 3

Mitochondrial restoration therapeutic programs.

Priority 4

AI-driven ventricular recovery prediction models.

Priority 5

SCF-derived regenerative cardiac API discovery program.

SCF-RDOS INDICATION SUMMARY

MASTER REGISTRY INDEX

SCF-RDOS-PPD-CV-001 — Peripartum Cardiomyopathy

SCF-PATH-0001 — SCF Pathophysiology Protocol (Universal Template)

SCF-SEF-MD-0001 — SCF Synergistic Evaluation Framework

SCF-CRD-WORKFLOW-0001 — SCF Clinical Research & Development Workflow

SCF-API-DP-0001 — SCF API Discovery Profile

SCF-RDOS-PPD-0001 — Postpartum Disorders & Diseases Registry

SCF-ENC-IND-CV-0001 — SCF Encyclopedia Entry Series: Cardiovascular Disorders